title: The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects.
abstract: Because of their locally invasive growth and high recurrence rate despite of aggressive local therapy, treatment of feline sarcomas is challenging. The tyrosine kinase inhibitor (TKI) toceranib is currently licensed for the treatment of canine mast cell tumours. There are only few reports about TKI usage in cats. Previous studies indicated promising potential of TKI for the treatment of feline injection site sarcoma (FISS). In this prospective clinical trial, 18 cats with unresectable FISS were treated at a target dosage of 3.25 mg kg-1every other day to evaluate the clinical efficacy and toxicity of toceranib. There was no clinical response measurable. Adverse events were generally mild and temporary. Grade 3 or 4 adverse events developed infrequently and all resolved with drug holidays and dose reductions.
authors.affiliation: Clinic of Small Animal Internal Medicine, Veterinaerstraße 13, Ludwig Maximilian University, 80539 Munich, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Holtermann
authors.affiliation: Institute of Pathobiology and Diagnostic Investigation, Michigan State University, Lansing, MI, USA.
authors.forename: M
authors.initials: M
authors.lastname: Kiupel
authors.affiliation: Clinic of Small Animal Internal Medicine, Veterinaerstraße 13, Ludwig Maximilian University, 80539 Munich, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Hirschberger
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy* / Q000209:etiology; D002415:Cats; D005260:Female; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D007267:Injections / Q000009:adverse effects / Q000662:veterinary*; D008297:Male; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary*
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; C464577:toceranib phosphate; D011505:Protein-Tyrosine Kinases
keywords: clinical pathology; comparative oncology; molecular diagnostics; oncology; surgical oncology; tyrosine kinase